Abstract: The present invention discloses the isolation and use of a specific bacterial promoter region suitable for use in constructs for the high level production of heterologous proteins. This promoter is derived from the bacterial gene encoding for alcohol dehydrogenase, in particular the alcohol dehydrogenase genes isolated from the thermophilic bacterial strain T. brockii and the mesophilic bacterial strain Clostridium beijerinckii. It is now disclosed that using either the intact promoter region or certain specific fragments consisting of at least a 88 bp DNA sequence in the upstream untranslated region of the bacterial alcohol dehydrogenase gene, operatively linked to the nucleic acid sequences encoding a heterologous protein, and insertion into a DNA plasmid or any other suitable vector system, heterologous genes can be expressed in high levels in host cells. Heterologous proteins or peptides can be expressed constitutively at high levels. The proteins are obtained in their active folded form.
Type:
Grant
Filed:
March 18, 2003
Date of Patent:
September 4, 2007
Assignees:
ProChon Biotech Ltd., Yeda Research and Development Co., Ltd.
Abstract: Chimeric polypeptides are disclosed that comprise a first polypeptide segment having histone acetyltransferase enzymatic activity and a second polypeptide segment that is similar to a subunit of a chromatin-associated histone deacetyltransferase protein complex. Also disclosed are nucleic acids encoding such chimeric polypeptides and eukaryotic organisms expressing such chimeric polypeptides.
Abstract: A transgenic rat containing in its genome a nucleotide sequence encoding a Ga subunit protein, which Ga protein subunit is uncoupled from regulation by Regulators of G-Protein Signaling (RGS) proteins, which Gx subunit protein is eventually the dominant-negative G188S mutant of Gax9, which nucleotide sequence is operatively associated with a neuron-specific expression control sequence, wherein the transgenic rat expresses the GA subunit protein in neural cells resulting in extended D-protein coupled receptor signaling mediated by the Ga subunit protein.
Type:
Grant
Filed:
April 24, 2001
Date of Patent:
August 28, 2007
Assignee:
Wyeth
Inventors:
Kathleen Young, David S. Howland, Karen L. Marquis, Sharon Rosenzweig-Lipson, Mark Ian Cockett
Abstract: The invention relates to isolated human pluripotent adult stem cells which express CD13, CD34, CD56 and CD117, and which do not express CD1O, which are capable of differentiating in all three germ lineages and differentiated cells derived therefrom.
Type:
Grant
Filed:
May 20, 2005
Date of Patent:
August 21, 2007
Inventors:
Paul Lucas, Sherri Schultz, Sharon P. Pine
Abstract: Purified nucleic acids, vectors and cells containing a gene cassette encoding at least one modified bioluminescent protein, wherein the modification includes the addition of a peptide sequence. The duration of bioluminescence emitted by the modified bioluminescent protein is shorter than the duration of bioluminescence emitted by an unmodified form of the bioluminescent protein.
Type:
Grant
Filed:
April 19, 2004
Date of Patent:
July 31, 2007
Assignee:
University of Tennessee Research Foundation
Inventors:
Michael S. Allen, Gupta Rakesh, Sayler S. Gary
Abstract: The polypeptide of the present invention has an activity of binding specifically to the cis-element of Chondromodulin-I (ChM-I) gene promoter and promoting the transcription of the ChM-I gene. The polypeptide of the present invention is usable in screening for a compound that promotes or inhibits the activity of the polypeptide.
Type:
Grant
Filed:
November 24, 2000
Date of Patent:
July 10, 2007
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Koji Yoshimura, Yuichi Hikichi, Kenichi Noguchi
Abstract: The invention provides for isolated nucleic acids encoding an Mda-5 polypeptide as shown in SEQ ID NO:1. The invention also provides for isolated nucleic acids comprising derivatives of the sequence of SEQ ID NO:1 that encode polypeptides functionally equivalent to Mda-5. The invention further provides for fragments of the isolated nucleic acid of SEQ ID NO:1 that encode polypeptides having Mda-5 biological activity. Vectors comprising these isolated nucleic acids and host cells comprising these vectors are also provided by the instant invention.
Type:
Grant
Filed:
February 29, 2000
Date of Patent:
June 12, 2007
Inventors:
Paul B. Fisher, Dong-Chul Kang, Rahul V. Gopalkrishnan
Abstract: Isolated GDF-9 regulatory sequences are disclosed, as well as methods of using the sequences to modulate tissue-specific expression of genes. The GDF-9 regulatory sequences include, for example, enhancer and promoter elements that naturally drive transcription of GDF-9 in specific tissues. The GDF-9 regulatory sequences can be derived from the untranscribed upstream (e.g., first 10 kilobases) and downstream regions, and transcribed, untranslated regions of a GDF-9 gene.
Type:
Grant
Filed:
March 31, 1999
Date of Patent:
June 5, 2007
Assignee:
Metamorphix, Inc.
Inventors:
Martin Matthew Matzuk, Julia Andrea Elvin
Abstract: The invention provides a method for preventing or treating male erectile dysfunction or female sexual arousal disorder by administering an effective amount of one or more factors from a group of factors including vascular endothelial growth factor, brain-derived neurotrophic factor, basic fibroblast growth factor, neurotrophin-3, neurotrophin-4, or angiopoietin-1, wherein the factor is a full length protein or a nucleic acid encoding the factor, or a functional derivative or fragment thereof, or an agent that enhances production and/or male erection or female sexual arousal stimulating function of the factor(s). Combinations, kits, and combinatorial methods are also provided.
Type:
Grant
Filed:
May 23, 2002
Date of Patent:
May 29, 2007
Assignee:
The Regents of the University of California
Inventors:
Tom F. Lue, Ching-Shwun Lin, Yuet W. Kan, Peter Carroll
Abstract: The present invention relates to a method of obtaining altered plasmid contents in bacteria, bearing mutation in at least one of the chromosomal genes, nusG, rho, and dnaC, and the bacterial strains thereof, having the mutated chromosomal genes, individually or in various possible combinations, capable of altering the level of plasmids.
Type:
Grant
Filed:
March 17, 2006
Date of Patent:
May 22, 2007
Assignee:
Centre for DNA Fingerprinting and Diagnostics (CDFD)
Abstract: The present invention provides novel cell lines that may have improved adhesive qualities, transgene expression level, growth rate, and/or growth rate in serum free medium or even chemically defined compared to cells of the prior art.
Type:
Grant
Filed:
March 22, 2004
Date of Patent:
May 15, 2007
Assignee:
Invitrogen Corporation
Inventors:
Sharon Cates, Valentina C. Ciccarone, Dale F. Gruber, Pamela Hawley-Nelson
Abstract: The present invention provides a protein having ?1,2-fucosyltransferase activity, a DNA encoding the protein, a recombinant DNA comprising the DNA, a transformant comprising the recombinant DNA, a process for producing the protein having ?1,2-fucosyltransferase activity using the transformant, and a process for producing a fucose-containing complex carbohydrate using the transformant.
Abstract: The present invention is directed to promoter sequences and promoter control elements, polynucleotide constructs comprising the promoters and control elements, and methods of identifying the promoters, control elements, or fragments thereof. The invention further relates to the use of the present promoters or promoter control elements to modulate transcript levels.
Abstract: The present invention provides methods and compositions for the diagnosis and treatment of cancer, including cancers involving the NOTCH pathway. In particular, the present invention provides methods and compositions for the diagnosis of mucoepidermoid carcinoma, the most common malignant salivary gland tumor. The present invention further provides methods and compositions for the diagnosis of other tumors associated with the t(11;19)(q14–21;12–13) translocation.
Type:
Grant
Filed:
July 3, 2002
Date of Patent:
May 8, 2007
Assignee:
United States of America, Represented by the Secretary, Department of Health and Human Services
Abstract: Telomerase repressor proteins and nucleic acid compositions encoding the same are provided. The subject repressor proteins bind to a repressor site in the TERT minimal promoter, e.g., a Site C site, and thereby inhibit TERT expression. Also provided are methods of modulating, e.g., inhibiting or enhancing, TERT expression. The subject invention finds use in a variety of different applications, including therapeutic and therapeutic agent screening applications.
Type:
Grant
Filed:
June 21, 2002
Date of Patent:
May 1, 2007
Assignee:
Sierra Sciences, Inc.
Inventors:
William H. Andrews, Christopher A. Foster, Stephanie Fraser, Hamid Mohammadpour, Laura Briggs
Abstract: Cellular libraries useful for in vitro phenotyping and gene mapping. In a representative approach, a method for preparing a homozygous cellular library includes the steps of providing a heterozygous cellular library comprising a plurality of isolated parent cells; inducing site-specific mitotic recombination in the plurality of isolated parent cells; culturing the plurality of isolated parent cells, whereby a population of daughter cells is produced; and selecting daughter cells comprising a homozygous genetic modification, whereby a homozygous cellular library is prepared.
Type:
Grant
Filed:
May 2, 2003
Date of Patent:
April 24, 2007
Assignee:
The University of North Carolina at Chapel Hill
Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp2, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. The polypeptides and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zacrp2 polypeptides.
Type:
Grant
Filed:
May 20, 2005
Date of Patent:
April 24, 2007
Assignee:
ZymoGenetics, Inc.
Inventors:
Christopher S. Piddington, Paul D. Bishop
Abstract: The present invention relates to cell-regulatory proteins and to nucleotide sequences encoding said proteins wherein the proteins have been found to be potential tumor and/or senescense markers useful for medical diagnostics and additionally having therapeutical potential as well as antiapoptotic properties useful for improving cell viability in cell culture technology. The invention further relates to antibodies directed against the cell-regulatory proteins and to their use in medical diagnostics and therapy. The invention further relates to methods for the manufacture and application of the cell-regulatory proteins and of the corresponding nucleotide sequences.
Abstract: The invention is concerned with the systematic elucidation and identification of regulatory sequences. The invention provides among others screenings and detection methods with which regulatory sequences can be identified. The invention further provides regulatory sequences and use thereof in various fields such as, but not limited to protein production, diagnostics, transgenic plants and animals, and the therapeutic field.
Abstract: Isolation and characterization of an oncosuppressive gene which is involved in the apoptotic process and is regulated by p53 ad p73, polypeptide thereby encoded, sequences involved in gene regulation and genetic constructs thereof.